NAYA Biosciences (NAYA) 10-Q 16 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 16, 2020
Document Information Line Items
Entity Registrant Name	INVO Bioscience, Inc.,
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		4,954,019
Amendment Flag	false
Entity Central Index Key	0001417926
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash	$ 908,289	$ 1,238,585
Accounts receivable	3,699	7,558
Inventory	241,484	101,387
Prepaid expenses and other current assets	218,667	195,910
Total current assets	1,372,139	1,543,440
Property and equipment, net of depreciation of $49,730 and $42,147 respectively	106,000	93,055
Capitalized patents, net of amortization of $71,843 and $70,488 respectively	5,879	7,234
Lease right of use	84,953	101,883
Trademarks	87,347	49,867
Investment in joint ventures	32,674	0
Total other assets	210,853	158,984
Total assets	1,688,992	1,795,479
Current liabilities
Accounts payable and accrued liabilities, including related parties	455,978	371,530
Accrued compensation – related party	532,592	393,017
Deferred revenue, current portion	714,286	714,286
Current portion of lease liability	22,356	21,365
Notes payable	157,620	0
Income taxes payable	0	912
Total current liabilities	1,882,832	1,501,110
Lease liability, net of current portion	64,436	81,494
Deferred revenue, net of current portion	3,035,714	3,571,429
Convertible notes, net of discount of $3,008,258 and $174,310 respectively	607,521	325,784
Convertible notes – related party, net of discount of $0 and $17,151 respectively	0	28,824
Deferred tax liability	433	433
Total liabilities	5,590,936	5,509,074
Stockholders’ deficiency
Preferred Stock, $.0001 par value; 100,000,000 shares authorized; No shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	0	0
Common Stock, $.0001 par value; 200,000,000 shares authorized; 4,953,910 and 4,884,879 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	495	489
Additional paid-in capital	24,525,427	20,174,682
Accumulated deficit	(28,427,866)	(23,888,766)
Total stockholders’ deficiency	(3,901,944)	(3,713,595)
Total liabilities and stockholders' deficiency	$ 1,688,992	$ 1,795,479

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Property and equipment, depreciation (in Dollars)	$ 49,730	$ 42,147
Capitalized patents, amortization (in Dollars)	$ 71,843	$ 70,488
Preferred Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	100,000,000	100,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	4,953,910	4,884,879
Common Stock, shares outstanding	4,953,910	4,884,879

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 336,071	$ 303,571	$ 840,714	$ 1,151,641
Cost of goods sold	27,398	44,926	78,562	111,186
Gross margin	308,673	258,645	762,152	1,040,455
Research and development	112,552	0	177,492
Selling, general and administrative expenses	1,463,887	891,008	4,311,872	2,087,725
Total operating expenses	1,576,439	891,008	4,489,364	2,087,725
Loss from operations	(1,267,766)	(632,363)	(3,727,212)	(1,047,270)
Interest expense	504,061	47,462	811,888	332,677
Total other ( income) expenses	504,061	47,462	811,888	332,677
Loss before income taxes	(1,771,827)	(679,825)	(4,539,100)	(1,379,947)
Provision for income taxes	0	(30,509)	0	(30,509)
Net loss	$ (1,771,827)	$ (710,334)	$ (4,539,100)	$ (1,410,456)
Basic net loss per weighted average shares of common stock (in Dollars per share)	$ (0.36)	$ (0.15)	$ (0.92)	$ (0.29)
Diluted net loss per weighted average shares of common stock (in Dollars per share)	$ (0.36)	$ (0.15)	$ (0.92)	$ (0.29)
Basic weighted average number of shares of common stock (in Shares)	4,946,125	4,861,377	4,932,405	4,847,074
Diluted weighted average number of shares of common stock (in Shares)	4,946,125	4,861,377	4,932,405	4,847,074
Product Revenue [Member]
Revenue	$ 157,500	$ 125,000	$ 305,000	$ 615,927
License [Member]
Revenue	$ 178,571	$ 178,571	$ 535,714	$ 535,714

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY DEFICIENCY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2018	$ 482	$ 18,996,517	$ (21,721,222)	$ (2,724,223)
Balance (in Shares) at Dec. 31, 2018	4,821,641
Common stock issues for settlement		26,600		26,600
Common stock issues for settlement (in Shares)	1,875
Conversion of notes payable and accrued interest	$ 1	53,722		53,723
Conversion of notes payable and accrued interest (in Shares)	8,394
Net loss			(458,570)	(458,570)
Balance at Mar. 31, 2019	$ 483	19,076,839	(22,179,792)	(3,102,470)
Balance (in Shares) at Mar. 31, 2019	4,831,910
Balance at Dec. 31, 2018	$ 482	18,996,517	(21,721,222)	(2,724,223)
Balance (in Shares) at Dec. 31, 2018	4,821,641
Stock issuance costs				0
Net loss				(1,410,456)
Balance at Sep. 30, 2019	$ 486	19,370,586	(23,131,678)	(3,760,606)
Balance (in Shares) at Sep. 30, 2019	4,862,379
Balance at Mar. 31, 2019	$ 483	19,076,839	(22,179,792)	(3,102,470)
Balance (in Shares) at Mar. 31, 2019	4,831,910
Conversion of notes payable and accrued interest	$ 3	184,997		185,000
Conversion of notes payable and accrued interest (in Shares)	28,907
Net loss			(241,552)	(241,552)
Balance at Jun. 30, 2019	$ 486	19,261,836	(22,421,344)	(3,159,022)
Balance (in Shares) at Jun. 30, 2019	4,860,817
Common stock issues for settlement		15,000		15,000
Common stock issues for settlement (in Shares)	1,562
Common stock issued for settlement		93,750		93,750
Net loss			(710,334)	(710,334)
Balance at Sep. 30, 2019	$ 486	19,370,586	(23,131,678)	(3,760,606)
Balance (in Shares) at Sep. 30, 2019	4,862,379
Balance at Dec. 31, 2019	$ 489	20,174,682	(23,888,766)	$ (3,713,595)
Balance (in Shares) at Dec. 31, 2019	4,884,879			4,884,879
Common stock issued to directors and employees	$ 4	303,459		$ 303,463
Common stock issued to directors and employees (in Shares)	40,569
Common stock issues for settlement		38,000		38,000
Common stock issues for settlement (in Shares)	5,001
Stock options issued to directors and employees as compensation		381,475		381,475
Net loss			(1,444,392)	(1,444,392)
Balance at Mar. 31, 2020	$ 493	20,897,616	(25,333,158)	(4,435,049)
Balance (in Shares) at Mar. 31, 2020	4,930,449
Balance at Dec. 31, 2019	$ 489	20,174,682	(23,888,766)	$ (3,713,595)
Balance (in Shares) at Dec. 31, 2019	4,884,879			4,884,879
Stock issuance costs				$ (106,316)
Net loss				(4,539,100)
Balance at Sep. 30, 2020	$ 495	24,525,427	(28,427,866)	$ (3,901,944)
Balance (in Shares) at Sep. 30, 2020	4,953,910			4,953,910
Balance at Mar. 31, 2020	$ 493	20,897,616	(25,333,158)	$ (4,435,049)
Balance (in Shares) at Mar. 31, 2020	4,930,449
Common stock issued to directors and employees		42,509		42,509
Common stock issued to directors and employees (in Shares)	3,437
Common stock issues for settlement	$ 1	22,799		22,800
Common stock issues for settlement (in Shares)	3,750
Stock options issued to directors and employees as compensation		214,915		214,915
Discount on convertible notes payable		1,879,542		1,879,542
Rounding shares as the result of reverse stock split (in Shares)	24
Net loss			(1,322,881)	(1,322,881)
Balance at Jun. 30, 2020	$ 494	23,057,381	(26,656,039)	(3,598,164)
Balance (in Shares) at Jun. 30, 2020	4,937,660
Common stock issued to directors and employees	$ 1	54,702		54,703
Common stock issued to directors and employees (in Shares)	12,500
Common stock issues for settlement		19,500		19,500
Common stock issues for settlement (in Shares)	3,750
Stock options issued to directors and employees as compensation		255,797		255,797
Discount on convertible notes payable		1,244,363		1,244,363
Stock issuance costs		(106,316)		(106,316)
Net loss			(1,771,827)	(1,771,827)
Balance at Sep. 30, 2020	$ 495	$ 24,525,427	$ (28,427,866)	$ (3,901,944)
Balance (in Shares) at Sep. 30, 2020	4,953,910			4,953,910

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (4,539,100)	$ (1,410,456)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Non-cash stock compensation issued for services	80,300	36,600
Non-cash stock compensation issued to employees	400,675	0
Stock to be issued for legal settlement	0	93,750
Fair value of stock options issued to employees	852,187	0
Amortization of discount on notes payable	465,525	297,058
Amortization of discount on notes payable options	59,324	0
Amortization of discount on notes payable warrants	71,430	0
Amortization of discount on notes payable issuance costs	81,764	0
Amortization of leasehold right of use asset	16,930	9,067
Depreciation and amortization	8,938	7,126
Changes in assets and liabilities:
Accounts receivable	3,859	198,878
Inventories	(140,097)	(25,817)
Prepaid expenses and other current assets	(22,757)	56,871
Accounts payable and accrued expenses	84,448	20,498
Leasehold liability	(16,067)	(8,456)
Deferred revenue	(535,715)	4,458,366
Accrued interest - related party	34,870	(55,553)
Accrued compensation	139,575	(1,566,834)
Income taxes payable	(912)	30,509
Net cash provided by (used in) operating activities	(2,954,823)	2,141,607
Cash from investing activities:
Payments to acquire property, plant and equipment	(20,528)	(64,839)
Net cash (used) in investing activities	(37,480)	(49,867)
Investment in joint venture	(32,674)	0
Net cash (used in) investing activities	(90,682)	(114,706)
Cash from financing activities:
Cash paid for notes payable	2,998,905	0
Proceeds from notes payable	157,620	0
Principal payments on note payable - related parties	(40,000)	(97,743)
Principal payment on notes payable	(295,000)	(131,722)
Payment of stock issuance expenses	(106,316)	0
Net cash (used in) provided by financing activities	2,715,209	(229,465)
Increase (decrease) in cash and cash equivalents	(330,296)	1,797,436
Cash and cash equivalents at beginning of period	1,238,585	212,243
Cash and cash equivalents at end of period	908,289	2,009,679
Cash paid during the period for:
Interest	83,134	84,043
Taxes	1,062	912
Leasehold right of use asset and leasehold liability upon adoption of ASU 2016-02, lease (Topic 842)	0	116,441
Common stock issued for conversion of notes payable and accrued interest	0	238,723
Common stock issued for prepaid services	0	5,000
Beneficial conversion feature on convertible notes	1,208,163	0
Fair value of shares issued with debt	868,985	0
Fair value of warrants issued with debt	999,464	0
Fair value of warrants issued related to debt placement	$ 47,293	$ 0

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 – Basis of Presentation The accompanying unaudited condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, the condensed consolidated statements of operations and stockholders’ deficiency for the three and nine months ended September 30, 2020 and 2019, and condensed consolidated statement of cash flows for the nine months ended September 30, 2020 and 2019 of INVO Bioscience, Inc. (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year. The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company’s annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31,2019 previously filed by the Company with the Securities and Exchange Commission (“SEC”) on March 30, 2020. The Company considers events or transactions that have occurred after the unaudited condensed consolidated balance sheet date of September 30, 2020, but prior to the filing of the unaudited condensed consolidated financial statements with the SEC on this Quarterly Report on Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]
Accounting Standards Update and Change in Accounting Principle [Text Block]	Note 2 – Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s consolidated financial position and results of operations. Recently Adopted Accounting Pronouncements In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of the new standard did not have an impact on the Company’s consolidated financial statements.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 3 – Going Concern On January 14, 2019, the Company entered into a distribution agreement (the “Distribution Agreement”) with Ferring International Center S.A. (“Ferring”) which granted Ferring an exclusive licensing rights to sublicense the Company’s patented INVOcell together with the retention device for the U.S. market. Under the terms of the Distribution Agreement, Ferring made an initial cash payment to the Company of $5,000,000 upon the execution of the Ferring distribution agreement in January 2019. For the nine months ended September 30, 2020 and 2019, the Company had net losses of $4,539,100 and $1,410,456, respectively. The Company had a working capital deficit of $510,693 as of September 30, 2020, compared to working capital of $42,330 as of December 31, 2019. As of September 30, 2020, the Company’s stockholder’s deficiency was $3,901,944 compared to $3,713,595 as of December 31, 2019 and cash used in operations was $2,954,823 for the nine months ended September 30, 2020 compared to cash provided by operations of $2,141,607 for the nine months ended September 30, 2019. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. Based on the Company’s projected cash needs, it will be dependent on generating sufficient sales, entering into new distribution agreements, or raising additional debt or equity capital to support the Company’s plans over the next 12 months.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 – Inventory As of September 30, 2020, and December 31, 2019, the Company recorded the following inventory balances: September 30, 2020 December 31, 2019 Raw Materials $ 99,363 $ 44,333 Work in Process 14,823 55,502 Finished Goods 127,298 1,552 Total Inventory $ 241,484 $ 101,387

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 – Property and Equipment The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of September 30, 2020 and December 31, 2019: Estimated Useful Life Manufacturing equipment 6 to 10 years Medical equipment 10 years Office equipment 3 to 7 years September 30, 2020 December 31, 2019 Manufacturing Equipment $ 132,513 $ 132,513 Medical equipment 20,528 - Office equipment 2,689 2,689 Less: Accumulated Depreciation (49,730 ) (42,147 ) Total $ 106,000 $ 93,055 During the three months ended September 30, 2020 and 2019, the Company recorded depreciation expense of $2,528 and $2,527, respectively. During the nine months ended September 30, 2020 and 2019, the Company recorded depreciation expense of $7,583 and $3,703, respectively.

Patents

Patents	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 – Patents As of September 30, 2020, and December 31, 2019, the Company recorded the following patent balances: September 30, 2020 December 31, 2019 Total Patents $ 77,722 $ 77,722 Accumulated Amortization (71,843 ) (70,488 ) Patent costs, net $ 5,879 $ 7,234 During the three months ended September 30, 2020 and 2019, the Company recorded $452 and $1,455, respectively, in amortization expenses related to patents. During the nine months ended September 30, 2020 and 2019, the Company recorded $1,355 and $3,423, respectively, in amortization expenses related to patents. Estimated amortization expense as of September 30, 2020 is as follows: Years ended December 31, 2020 – remaining three months $ 454 2021 1,809 2022 1,809 2023 and thereafter 1,807 Total $ 5,879 As of September 30, 2020, and December 31, 2019, the Company recorded the following trademarks balances: September 30, 2020 December 31, 2019 Total Trademarks $ 87,347 $ 49,867 Trademarks $ 87,347 $ 49,867 The increase in the trademark assets of $37,480 was the result of additional legal fees. The trademarks have an indefinite life, so no amortization expense is calculated. Trademarks are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The Trademark assets were created in 2019, and no material adverse changes have occurred since their creation.

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Disclosure Text Block [Abstract]
Lessor, Operating Leases [Text Block]	Note 7 – Leases The Company has an operating lease for its facility, which has a remaining term of 5 years with an option to renew for three additional years. They also do not have an early termination clause included. The Company’s operating lease agreements does not contain any material restrictive covenants. As of September 30, 2020, the Company's lease components included in the consolidated balance sheet were as follows: Lease component Classification September 30, 2020 Assets ROU assets - operating lease Other assets $ 84,953 Total ROU assets $ 84,953 Liabilities Current operating lease liability Current liabilities $ 22,356 Long-term operating lease liability Other liabilities 64,436 Total lease liabilities $ 86,792 Rent expense is recognized on a straight-line basis over the life of the lease. Rent expense consists of the following: Nine months ended September 30, 2020 Operating lease costs $ 18,924 Short term lease cost - Total rent expense $ 18,924 Future minimum lease payments under non-cancellable leases were as follows: September 30, 2020 2020 - remaining three months $ 6,088 2021 24,839 2022 25,585 2023 26,352 2024 8,870 Total future minimum lease payments $ 91,734 Less: Interest (4,942 ) Total operating lease liabilities $ 86,792 Current operating lease liability $ 22,356 Long-term operating lease liability 64,436 Total operating lease liabilities $ 86,792

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	Note 8 – Notes Payable Notes Payable In August 2016, the Company converted a long-time vendor’s outstanding accounts payable balance of $131,722 into a promissory note with a three year term that accrues interest at 5% per annum. The note provided for interest-only payments on the first and second anniversaries of the note. The note was payable in full along with any outstanding accrued interest on August 9, 2019 The Note and all accrued interest were paid in full on January 25, 2019 and as of September 30, 2020, the balance is $0. The interest on this note for the nine months ended September 30, 2019 was $489. 2018 Convertible Notes Payable In April and May 2018, the Company issued convertible notes (the “2018 Convertible Notes”) payable to investors in the aggregate principal amount of $895,000. The 2018 Convertible Notes accrued interest at the rate of 9% per annum which was payable in stock. The 2018 Convertible Notes in an aggregate principal amount of $550,000, were due on January 30, 2020, and 2018 Convertible Notes with an aggregate principal amount of $345,000 were due on March 31, 2021. The notes were convertible into shares of common stock at a price of $6.40 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes could elect to convert the notes in shares of the Company’s common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the fourth quarter of 2018, three note holders converted their notes with a value of $200,000 into 32,982 shares of common stock. During the nine months ended September 30, 2019, 2 note holders converted principal and accrued interest of $235,000 and $3,723, respectively, into a total of 37,301 shares of common stock. At inception of issuance, the Company calculated a beneficial conversion feature of the 2018 Convertible Notes in the form of a discount of $895,000; In May 2020, the remaining balance of $396,044, which included the principal balance of $420,000, accrued interest of $94,419, and the conversion discount of $118,375, was repaid. As part of the extinguishment of the 2018 Convertible Notes, the Company issued 2020 Convertible Notes (as described below) to two remaining holders in the amount of $143,640. The remaining balance related to these notes was $116,693, which was comprised of a principal balance of $125,000, accrued interest of $23,318, net of the remaining discount of $31,625. In accordance with ASC 470, the extinguishment for these two holders was accounted for as a modification and no gain or loss was recorded. In May 2020, the remaining balance of $35,483, which included the principal balance of $40,000, accrued interest of $7,355, and a conversion discount of $11,872, was repaid. As of September 30, 2020, the balance of the 2018 Convertible Notes is $0. 2020 Convertible Notes Payable From May 2020 through July 2020, the Company issued convertible notes (the “2020 Convertible Notes”) payable to investors in the aggregate principal amount of approximately $3.5 million. The 2020 Convertible Notes accrue interest at the rate of 10% per annum and are due in November, December 2021and January 2022. The Company calculated a beneficial conversion feature of approximately $1,208,163 and also incurred professional fees of approximately $371,000 related to this issuance resulting in a total discount related to these two items of approximately $1,579,163. The notes are convertible into shares of common stock at an exercise price of $5.76 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2020 Convertible Notes can elect to convert the principal and any accrued but unpaid interest on the notes into shares of the Company’s common stock at a price equal to the price per share paid in such subsequent equity financing. In connection with the issuance of the 2020 Convertible Notes, the Company also issued 303,623 unit purchase options to purchase 303,623 units at an exercise price of $8.00 per unit, with each unit consisting of one share of common stock and one warrant to purchase common stock at an exercise price of $9.60 per share. The units and warrants are exercisable for a period of five years from the date of issuance, are subject to a downward provision if the Company issues securities at a lower price, and warrant holders have a right to require the Company to pay cash in the case of a fundamental transaction. In accordance with ASC 815, the warrants and options issued in this period were determined to require equity treatment. In connection with the recent convertible note private placement, INVO agreed to issue to the placement agent and the selling agent five-year warrants to purchase 6,750 shares of the Company’s common stock at an exercise price of $5.76. Of the $3.5 million in net proceeds received in the offering at September 30, 2020, $2.2 million was allocated to the unit purchase options issued to investors based on their relative fair value. This amount represented a discount on the debt and additional paid-in-capital at the date of issuance. Principal balances of the 2020 Convertible Notes were as follows: September 30, 2020 December 31, 2019 2020 Convertible Notes 3,494,840 - Accrued interest 120,939 - Less beneficial conversion feature discount (934,769 ) - Less options discount (809,649 ) - Less warrants discount (974,669 ) - Less issuance cost (289,171 ) - Total, net of discount $ 607,521 $ - Interest expense on the 2020 Convertible Note was $89,158 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $120,939 and $0 of interest expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. Amortization of options discount on the 2020 Convertible note was $43,769 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $59,334 and $0 of amortization expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. Amortization of warrant discount on the 2020 Convertible Note was $52,688 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $71,430 and $0 of amortization expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. Amortization of beneficial conversion feature on the 2020 Convertible Note was $257,455 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $274,064 and $0 of amortization expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. Amortization of issuance costs on the 2020 Convertible Note was $61,187 and $0 for the three months ended September 30, 2020 and 2019, respectively. In addition, $81,764 and $0 of amortization expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. On July 1, 2020, the Company received a loan in the principal amount of $157,620 relating to the U.S. Small Business Administration’s Paycheck Protection Program. The loan will mature 18 months from the date of funding is payable over 18 equal monthly installments, and bears interest at a rate of 1% per annum. The loan is forgivable up to 100% of the principal balance based upon satisfaction of certain criteria under the Paycheck Protection Program.

Notes Payable and Other Related

Notes Payable and Other Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 9 – Notes Payable and Other Related Party Transactions In April 2011, the Company issued a new short-term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000. The Note carries a 10% interest rate. The Company paid $25,000 of the Note in 2011 in cash. The Q211 Note is convertible into Common Stock of the Company at a conversion price of $0.96 per share, subject to adjustments. During the three and nine months ended September 30, 2019, the Company accrued interest in the amount of $597 and $1,836 on the Q211 Note, respectively. In November 2011, the Company issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000. The Q411 Note carries a 10% interest rate. The Q411 Note was converted into common stock of the Company at a conversion price of $0.32 per share, subject to adjustments. During the three and nine months ended September 30, 2019, the Company accrued interest in the amount of $253 and $749 on the Q411 Note, respectively. The foregoing notes had maturity dates thirty days subsequent to the dates of issuance. Interest was calculated at 10% per annum, compounded based on a 360-day year. Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $.96 and $.32, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.21). On August 7, 2019, the Company sent James Bowdring, a related party, a check in the amount of $65,197 as full payment of the foregoing promissory notes. On August 8, 2019, Mr. Bowdring’s legal counsel returned this check with a letter stating that the check did not properly account for the compound interest identified in such notes. In addition, the letter stated Mr. Bowdring’s desire to convert these promissory notes into shares of the Company’s common stock in lieu of any cash payment. The Company does not believe that Mr. Bowdring has the right to convert such notes upon receiving payment of such notes and intends to vigorously contest any conversion of these notes. In May 2018, James Bowdring and his children participated in the “2018 Convertible Notes” offerings in the aggregate principal amount of $40,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. These Notes are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $6.40 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of the Company’s common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the three months ending September 30, 2020 and 2019, $0 and $907 of interest was accrued, respectively. In addition, $1,380 and $2,692 of interest was accrued in the nine months ended September 30, 2020 and 2019, respectively. In May 2018, the Company sold 4,687 shares of common stock at a price of $6.40 per share for proceeds of $30,000 to Charles Mulrey and family, the brother-in-law of Robert J. Bowdring, Director & Acting Chief Financial Officer as part of the recent financing. During the second quarter of 2018, INVO Bioscience settled a commitment it had with one of its Directors, Dr. Kevin Doody for the services he and his team performed prior to and following INVOcell’s FDA clearance related to clinical guidance and support. The Company issued him 93,750 common shares of stock with a fair value of $1,530,000. The Company previously rented its corporate office from Forty Four Realty Trust which is owned by James Bowdring, the brother of former Director and former Interim CFO, Robert Bowdring from November 2012 through May 2019 when the Company relocated to a new facility. It was a month to month rental arrangement for less than the going fair market real estate rental rate. The rent expense paid for the nine months ended September 30, 2020 and 2019 was $0 and $1,800 respectively. In addition, the Company had purchased stationary supplies and marketing items at discounted rates from Superior Printing & Promotions which is also owned by James Bowdring and is in the same building as the Company’s former corporate office. INVO Bioscience spent $0 and $2,134 with Superior during the three months ended September 30, 2020 and 2019, respectively, spent $0 and $8,168 during the nine months ended September 30, 2020 and 2019, respectively. Principal balances of the related party loans were as follows: September 30, 2020 December 31, 2019 James Bowdring Family – 2018 Convertible Notes - 45,975 Less discount - (17,151 ) Total, net of discount $ - $ 28,824 Interest expense on related party loans was $0 and $1,271 for the three months ended September 30, 2020 and 2019, respectively. In addition, $1,380 and $4,792 of interest expense was recorded in the nine months ended September 30, 2020 and 2019, respectively. Accounts payable and accrued liabilities balances include accrued directors fees, expenses reports for management and employees for expenses they paid for personally related to travel or normal business expenses. September 30, December 31, 2020 2019 Accounts payable and accrued liabilities $ 5,756 $ 13,018

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 10 – Stockholders’ Equity Reverse Stock Split On December 16, 2019, the Company’s stockholders approved a reverse stock split at a ratio of between 1-for 5 and 1-for-25, with discretion for the exact ratio to be approved by the Company’s board of directors. On February 19, 2020, the Company’s board of directors approved a reverse stock split of the Company’s common stock at a ratio of 1-for-20. On May 21, 2020, the Company filed a certificate of change (with an effective date of May 26, 2020) with the Nevada Secretary of State pursuant to Nevada Revised Statutes 78.209 to effectuate a 1-for-20 reverse stock split of its outstanding common stock. The reverse split took effect at the open of business on May 26, 2020. On October 22, 2020 the Company’s board of directors approved a reverse stock split of the Company’s common stock at a ratio of 5-for-8 and also approved a proportionate decrease in the Company’s authorized common stock to 125,000,000 shares from 200,000,000. Pursuant to Nevada Revised Statutes, a company may effect a reverse split without stockholder approval if both the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced as a result of the reverse split, the reverse split does not adversely affect any other class of stock of the company, and the company does not pay money or issue scrip to stockholders who would otherwise be entitled to receive a fractional share as a result of the reverse split. On November 5, 2020, the Company filed a certificate of change (with an effective date of November 9, 2020) with the Nevada Secretary of State pursuant to Nevada Revised Statutes 78.209 to effectuate a 5-for-8 reverse stock split of its outstanding common stock. On November 6 , 2020, the Company received notice from FINRA/OTC Corporate Actions that the reverse split would take effect at the open of business on November 9, 2020 and the reverse stock split took effect on that date. During the three months ended September 30, 2020 we incurred $106,316 of offering costs related to issuance of common stock. Nine Months Ended September 30, 2020 In January 2020, the Company issued 31,250 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $221,400 to an officer. In February 2020, the Company issued 3,125 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $24,750 to an employee of which $14,438 was amortized in the nine months ended September 30, 2020. In February 2020, the Company issued 3,098 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,000 to a board member. In February 2020, the Company issued 3,098 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,000 to a board member. In February 2020, the Company issued 1,875 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $15,000 for services. In February 2020, pursuant to Section 4(a)(2) of the Securities Act of 1933 as amended (the “Securities Act”), the Company issued 1,563 shares of common stock with a fair value of $11,500 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. In March 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,563 shares of common stock with a fair value of $11,500 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. In May 2020, pursuant to Section 3(a)(9) of the Securities Act, the Company issued 24 shares of common stock as the result of the rounding on the reverse stock split. The Company did not receive any proceeds from the issuance. In May 2020, the Company issued 3,438 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,930 to an employee of which $12,804 was amortized in the nine months ended September 30, 2020. In June 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,750 shares of common stock with a fair value of $22,800 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. In August 2020, the Company issued 12,500 shares of restricted stock under its 2019 Stock Incentive Plan with a fair value of $72,200 to an employee of which $12,032 was amortized in the nine months ended September 30, 2020. In August 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,750 shares of common stock with a fair value of $19,500 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. Nine Months Ended September 30, 2019 In January 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,875 shares of common stock with a fair value of $26,600 to service providers. In February 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 8,394 shares of common stock for conversion of notes payable and accrued interest in the amount of $53,723. In April 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 25,000 shares of common stock for conversion of notes payable in the amount of $160,000. In May 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,907 shares of common stock for conversion of notes payable in the amount of $25,000. In August 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,562 shares of common stock with a fair value of $15,000 to service providers.

Stock Options and Warrants

Stock Options and Warrants	9 Months Ended
	Sep. 30, 2020
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	Note 11 – Stock Options and Warrants Equity Incentive Plans In October 2019, the Company adopted its 2019 Stock Incentive Plan (the "2019 Plan"). Under the 2019 Plan, the Company’s Board of Directors is authorized to grant both incentive and non-statutory stock options to purchase common stock and restricted stock awards to its employees, directors, and consultants. The 2019 Plan initially provided for the issuance of 500,000 shares. However, in January 2020, under the terms of the plan, the number of available shares issuable increased to 793,093 shares as the aggregate number of shares under the Plan automatically increases on January 1st of each year, in an amount equal to six percent (6%) of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year. Options generally have a life of 3 to 10 years and exercise price equal to or greater than the fair market value of the Common Stock as determined by the Company’s Board of Directors. Vesting for employees typically occurs over a three-year period or based on performance objective. The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. The prices represent the closing price of the Company’s Common Stock on the OTCQB Market on the respective dates. Options Outstanding Options Exercisable Number of Shares Price per Share Range Weighted Average Exercise Price Aggregate Intrinsic Value (1) Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value (1) Balance at December 31, 2019 260,018 $ 8.16-9.25 $ 8.41 $ - 11,256 $ 8.16 $ - Forfeited - $ - $ - - - - - Vested - - - - 140,399 6.48 - Exercised - $ - $ - - - - - Granted 328,303 $ 5.76-8.32 $ 6.47 - - - - Balance at September 30, 2020 588,321 $ 5.76-9.25 $ 7.32 $ - 151,655 $ 7.16 $ - (1) The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Nine Months ended September 30, 2020 2019 Risk-free interest rate range 0.48 to 1.65 % - % Expected life of option-years 5.20 to 5.77 - Expected stock price volatility 110.8 to 128.0 % - % Expected dividend yield - % - % The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of the Company’s common stock over the period commensurate with the expected term of the related instrument. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executives, within the Company. The Company does not currently pay dividends on its common stock nor does it expect to do so in the foreseeable future. Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Life in Years Weighted Average Exercise Price Options Exercisable Weighted Average Exercise Price of Options Exercisable Year ended December 31, 2019 $ 8.16-9.25 260,018 2.6 $ 8.41 11,256 $ 8.16 Nine Months ended September 30, 2020 $ 5.76-9.25 588,321 3.7 $ 7.32 151,655 $ 7.16 Total Intrinsic Value of Options Exercised Total Fair Value of Options Vested Year ended December 21, 2019 - 69,787 Nine months ended September 30, 2020 $ - $ 910,444 For the nine months ended September 30, 2020, the weighted average grant date fair value of options granted was $5.44 per share. The Company estimates the fair value of options at the grant date using the Black-Scholes model. For all stock options granted through September 30, 2020, the weighted average remaining service period is 3.7 years. The Company recognized $259,547 and $0 in stock-based compensation expense, which is recorded in selling, general and administrative expenses on the consolidated statement of operations for the three months ended September 30, 2020 and 2019, respectively. In addition, the Company recognized $852,187 and $0 in stock-based compensation expense, which is recorded in selling, general and administrative expenses on the consolidated statement of operations for the nine months ended September 30, 2020 and 2019, respectively. Unamortized stock option expense at September 30, 2020 that will be amortized over the weighted-average remaining service period totaled $2,107,857. Restricted Stock and Restricted Stock Units In the nine months ended September 30, 2020, the Company issued 90,412 shares of restricted stock, to certain employees and directors. Shares issued to employees and directors are generally either vest at grant or vest over a period of one year from grant. In the nine months ended September 30, 2020, 50,871 shares of restricted stock vested. The following table summarizes the Company’s aggregate restricted stock awards and restricted stock unit activity during the nine months ended September 30, 2020: Number of Unvested Shares Weighted Average Grant Date Fair Value Aggregate Value of Unvested Shares Balance at December 31, 2019 10,417 $ 9.60 $ 100,000 Granted 56,509 $ 6.98 $ 394,280 Vested (50,871 ) $ 7.63 $ (388,173 ) Forfeitures (- ) $ - $ (- ) Balance at September 30, 2020 16,055 $ 6.61 $ 106,107 The Company recognized $67,202 and $388,173 in stock-based compensation expense for the three and nine months ended September 30, 2020, respectively. It will recognize $106,107 over the remaining requisite service period. Stock-based compensation expense is recorded in selling, general and administrative expenses on the consolidated statement of operations In October 2019, the Company issued 12,500 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $120,000 to an officer, of which $90,000 was amortized in the nine months ended September 30, 2020. Warrants In connection with the issuance of the 2020 Convertible Notes, the Company also issued 310,373 unit purchase options to purchase 310,373 units at an exercise price of $8.00 per unit, with each unit consisting of one share of common, and a warrant to purchase one share of common stock at an exercise price of $9.60 per share. The units and warrants are exercisable for a period of five years from the date of issuance and are subject to a downward provision if the Company issues securities at a lower price. Warrant holders have a right to require the Company to pay cash in the event of a fundamental transaction. In accordance with ASC 815, the warrants and options issued in this period were determined to require equity treatment and $868,973 related to the options and $998,818 related to warrants was recorded in equity in the nine months ended September 30, 2020. In connection with the issuance of the 2020 Convertible Notes, the Company agreed to issue the placement agent and the selling agent five-year warrants to purchase 6,750 shares of the Company’s common stock at an exercise price of $5.76. In the nine months ended September 30, 2020, $47,293 was recorded in equity related to these warrants. A Monte Carlo model was used because the investor warrants and options contain fundamental transaction payouts and reset events that cannot be modeled with a Black Scholes model. The fair value of the options and warrants issued to the convertible debt holders is estimated as of the issue date using a Monte Carlo model with the following assumptions: Nine Months ended September 30, 2020 2019 Risk-free interest rate range 0.33% - 0.39 % - % Stock Price $3.00 - $3.95 - % Expected life of warrants and option (years) 5.00 - % Expected stock price volatility 108.2% - 112.5 % - % Expected dividend yield 0 % - % The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options and warrants. Expected volatility is based upon the historical volatility of the Company’s common stock over the period commensurate with the expected term of the related instrument. The options and warrants are valued assuming projected reset events adjusting the exercise price and a forced exercise upon a projected fundamental transaction by management. The options and warrants early exercise are modeled assuming registration after 180 days. We do not currently pay dividends on our common stock nor do we expect to in the foreseeable future.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 12 – Income Taxes The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. Currently, a valuation allowance is established for all DTA’s and carryforwards as their recoverability is deemed to be uncertain. If the Company’s expectations for future operating results at the federal or at the state jurisdiction level vary from actual results due to changes in healthcare regulations, general economic conditions, or other factors, it may need to adjust the valuation allowance, for all or a portion of the Company’s deferred tax assets. The Company’s income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in the Company’s valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on the Company’s future earnings. Income tax expense was $0 and $30,509 for the nine months ended September 30, 2020 and 2019. The annual forecasted effective income tax rate for 2020 is 0% with a year-to-date effective income tax rate for the three and nine months ended September 30, 2020 respectively of 0%.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 13 – Commitments and Contingencies A) Litigation INVO Bioscience, Inc. v. James Bowdring On August 7, 2019, the Company sent James Bowdring, the brother of the Company’s then Chief Financial Officer, a check in the amount of $65,197 as full and final payment under those certain promissory notes dated April 8, 2011 and November 9, 2011. On August 8, 2019, Mr. Bowdring’s legal counsel returned the check. A basis for returning the check was a claim that the interest due under the Notes called for compounded interest and not per annum interest. In addition, the letter rejecting the tender of the payment in full check alleged Mr. Bowdring was considering a future intention to convert his Promissory Notes into shares of the Company’s common stock. Mr. Bowdring, through his counsel, indicated that such future intention to convert the Notes to common stock were contingent upon Mr. Bowdring addressing certain personal issues which were not disclosed by his counsel in the correspondence returning the checks. The Company does not believe that Mr. Bowdring has the right to seek conversion of the Notes once payment for the Notes has been tendered. In order to resolve the issue of the Company’s tender of payment in full versus Mr. Bowdring’s assertion that he can reject tender and seek conversion, the Company has filed an action in the Suffolk Superior Court in Boston on September 3, 2019 seeking Declaratory Judgment and Judgment for Breach of Contract. On September 30, 2019, Mr. Bowdring filed an answer and counterclaim under which he alleged breach of contract, fraud, promissory estoppel, unfair and deceptive practices and constructive trust. Mr. Bowdring is seeking receipt of all shares due under the adjusted conversion price. The 10% Senior Secured Convertible Promissory Notes were issued on April 8, 2011 and November 9, 2011, with maturity dates thirty days subsequent to the dates of issuance. Interest was calculated at 10% per annum, compounded based on a 360-day year. Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $0.96 and $0.32, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.2100). The Company does not currently expect the above matter to have a material adverse effect upon either the Company’s results of operations, financial position, or cash flows. B) Employee Agreements On October 10, 2019, the Company entered into an agreement with its CEO, Steve Shum. The Company agreed to pay Mr. Shum an annual salary of $260,000. In addition, Mr. Shum is eligible to earn bonus compensation of up to $75,000 bonus upon a successful up-listing to the NASDAQ exchange. All other bonus amounts will be determined by the Board of Directors, in their sole discretion. In addition to his base salary and performance bonus, the Company granted Mr. Shum: (i) 12,500 shares of common stock and (ii) a three-year option to purchase 202,599 shares of common stock at an exercise price of $8.16 per share. These options will vest monthly over a 3-year period. On January 15, 2020, the Company entered into an employment agreement (the “ Employment Agreement In connection with the Employment Agreement, on January 17, 2020, the Company granted Mr. Campbell 31,250 shares of Company common stock, and an option to purchase 125,000 shares of Company common stock (the “ Option The Company has entered into a consulting agreement with Shine Management, Inc. through which it is receiving outsourced accounting and the support of its acting CFO, Debra Hoopes. Debra is the CFO and Chief Administrative Officer of Shine Management, Inc. and Management Services Company in Charlottesville, VA.

Contracts with Customers

Contracts with Customers	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 14 – Contracts with Customers The Company has adopted ASC 606, Revenue from Contracts with Customers . Revenue Recognition Revenues for products, including: INVOcell®, INVO TM Retention System, and INVO Microscope Holding Block are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenues from consignment are recognized when the medical device is shipped from the Consignor to the customer. In January 2019, the Company announced a U.S. license and distribution agreement with Ferring International Center S.A. (“Ferring”) and as a result took a significant step to strengthen the Company that the Company believes will allow it to implement its overall business plan. The Company believes that this strategic partnership with a strong reproductive organization such as Ferring Pharmaceuticals will provide it with the necessary sales and marketing resources within the United States to expand the market and help reach all of those couples not receiving reproductive treatments today. The agreement calls for the issuance of an initial upfront payment of $5,000,000 which the Company received upon the signing of the agreement and then subsequent licensing fee payment of $3,000,000 that will provide the Company with a source of non-dilutive financing to execute the Company’s plan. Under the terms of the agreement the Company can pursue developing international markets and as well as partnering and opening INVO-only reproductive centers within the U.S. market. The Company believes this major milestone and agreement is a critical step that allows the Company to implement its mission of expanding access to care in the fertility marketplace. The initial upfront payment of $5,000,000 which the Company received upon the signing of the agreement is being recognized to income over the 7 year term. Under the terms of the Distribution Agreement, Ferring completed its obligation to make an initial payment to the Company of $5,000,000 upon completion of the required closing conditions, including executed agreements from all current manufacturers of the licensed product that upon a material supply default by the Company, Ferring can assume a direct purchase relationship with such manufacturers. Ferring is obligated to make a second payment to the Company of $3,000,000 provided that the Company is successful in obtaining a five day label enhancement from the FDA for the current incubation period for the licensed product at least three (3) years prior to the expiration of the term of the license for the licensed product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, the Company entered into a separate Distribution Agreement. The Distribution Agreement has an initial term expiring on December 31, 2025 and at the end of the initial term it may be terminated by the Company if Ferring fails to generate specified minimum revenues to the Company from the sale of the licensed product during the final two years of the initial term. The Ferring license was deemed to be a functional license that provide customers with a “right to access” to the Company’s intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. During the three months and nine months ended September 30, 2020, the Company recognized $178,572 and $357,143, respectively, related to the Ferring license agreement. As of September 30, 2020, and December 31, 2019, the Company had deferred revenues of $3,750,000 and $4,285,715, respectively. On September 20, 2019, the Company entered into an exclusive distribution agreement with Quality Medicines, Cosmetics & Medical Equipment Import for the territories of Sudan, Uganda and Ethiopia. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. Quality Medicines is required to register the Company’s product in each of these countries. We expect to renew or extend this agreement for another year. On September 11, 2019, the Company entered into an exclusive distribution agreement with G-Systems Limited registered in Nigeria. In the territories of Nigeria. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. G-Systems is required to register the Company’s product in Nigeria. We expect to renew or extend this agreement for another year. On November 12, 2019, the Company announced that it had entered into exclusive distribution agreements with Biovate a Jordanian company for the territory of Jordan and Orcan Medical for the territory of Turkey. This agreement has a term of one year with extensions by mutual agreement. Safadi Drugstore is required to register the Company’s product in Jordan. We expect to renew or extend this agreement for another year. On January 16, 2020, the Company announced a Joint Venture agreement for the India market. Under terms of the agreement, The Company and its partner, Medesole Healthcare and Trading Pvt Ltd, will each own 50% of the joint venture. The Company provides the device, training and general technology support to the joint venture, while Medesole will be responsible for the operations of the INVOcell clinics in India. Both partners will equally invest in start-up and capital expenditures and share in the revenue and profits of the joint venture. The business model allows the Company to benefit not only from the sale of the device, but from the delivery of the entire solution. The Company believes this JV structure is an attractive new model for us, and one in which the Company may replicate in other select parts of the world. As of September 30, 2020 the final JV setup had not yet been completed. Sources of Revenue The Company has identified the following revenues disaggregated by revenue source: Domestic Physicians – direct sales of products concluded in January 2019 Domestic Distributor - sales to Ferring who then sells to physicians Domestic Licensing fee International Distributors – direct sales of products. For the nine months ended September 30, 2020 and 2019 the source of revenue was derived from: September 30, 2020 September 30, 2019 Domestic Product revenue $ 305,000 $ 615,927 Domestic licensing fee 535,714 535,714 Total revenue $ 840,714 $ 1,151,641 The Company’s revenue is highly concentrated as 100 percent of revenue is currently derived from the Company’s agreement with Ferring. Contract Balances The Company incurs agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, the Company has determined that the balance related to these obligations is generally immaterial at any point in time. The Company monitors the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty The Company’s general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Commissions and Contract Costs The Company does not use or offer sales commissions of any type at this time. The Company generally does not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement. Practical Expedients The Company’s payment terms for sales direct to customers and distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as an offset to the costs for shipping and handling of products included as a component of cost of products. Taxes Collected from Customers As the Company’s products are used in another service and are exempt, the Company does not collect taxes. If the Company were to collect taxes, they would be assessed on the value of transaction revenue and would be excluded from product revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities. Effective Date and Transition Disclosures Adoption of the new standards did not have a material impact on the Company’s consolidated financial statements and is not expected to have a material impact in future periods.

Investment in Joint Ventures

Investment in Joint Ventures	9 Months Ended
	Sep. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	Note 15 – Investment in Joint Ventures Effective September 24, 2020, the Company’s wholly owned subsidiary, INVO Centers, LLC a Delaware limited liability company (“INVO Centers”) entered into a Pre-Incorporation and Shareholders Agreement (the “ Agreement The Mexico Company, which will be named Positib Fertility, S.A. de C.V, is to be established within three weeks of executing the Agreement, with each of INVO Centers, Arredondo and Ramirez to be equal shareholders (1/3 each). The Mexico Company will acquire exclusively from INVO Bioscience, Inc. the INVOcell product to be used by the Mexico Company to render its services at cost plus any uncured shipping, customs and related fees. The joint venture partners have begun the process to identify key personnel, started the build out, and have requested approval from Cofepris (the Mexico Ministry of Health). The Company believes that, the earliest possible operational timeframe for the joint venture is second quarter of 2021. The Shareholders agree that the Mexico Company will operate in Monterrey Nuevo Leon, Mexico and any other cities and places in Mexico as approved by the Mexico Company board of directors and Shareholders. In addition, the Shareholders agree that the Mexico Company will be the exclusive distributor of INVO Bioscience, Inc. and affiliates with respect to the INVO Products in Mexico and the Shareholders agree not to compete directly or indirectly with the Mexico Company in Mexico. Each Shareholder agreed to certain restrictions on transfer of its equity in the Mexico Company and afforded the other Shareholders a right of first refusal prior to any transfer. In addition, the Company has invested $9,157 in joint ventures the Company is currently exploring.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 16 – Subsequent Events The Company issued 109 rounding shares in conjunction with the reverse stock split of the Company’s common stock at a ratio of 5-for-8. On November 12, 2020, the Company entered into an underwriting agreement (the “ Underwriting Agreement Underwriters Offering Firm Shares Common Stock Option Shares Shares The Company expects to close the sale of the Common Stock on November 17, 2020, subject to customary closing conditions. The net proceeds to the Company from the Offering are expected to be approximately $10.1 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company has evaluated subsequent events through the date the financial statements were released and there were no others.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	As of September 30, 2020, and December 31, 2019, the Company recorded the following inventory balances: September 30, 2020 December 31, 2019 Raw Materials $ 99,363 $ 44,333 Work in Process 14,823 55,502 Finished Goods 127,298 1,552 Total Inventory $ 241,484 $ 101,387

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2020
Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of September 30, 2020 and December 31, 2019: September 30, 2020 December 31, 2019 Manufacturing Equipment $ 132,513 $ 132,513 Medical equipment 20,528 - Office equipment 2,689 2,689 Less: Accumulated Depreciation (49,730 ) (42,147 ) Total $ 106,000 $ 93,055
Estimated Useful Life [Member]
Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of September 30, 2020 and December 31, 2019: Estimated Useful Life Manufacturing equipment 6 to 10 years Medical equipment 10 years Office equipment 3 to 7 years

Patents (Tables)

Patents (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of September 30, 2020, and December 31, 2019, the Company recorded the following patent balances: September 30, 2020 December 31, 2019 Total Patents $ 77,722 $ 77,722 Accumulated Amortization (71,843 ) (70,488 ) Patent costs, net $ 5,879 $ 7,234
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense as of September 30, 2020 is as follows: Years ended December 31, 2020 – remaining three months $ 454 2021 1,809 2022 1,809 2023 and thereafter 1,807 Total $ 5,879
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	As of September 30, 2020, and December 31, 2019, the Company recorded the following trademarks balances: September 30, 2020 December 31, 2019 Total Trademarks $ 87,347 $ 49,867 Trademarks $ 87,347 $ 49,867

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Disclosure [Table Text Block]	As of September 30, 2020, the Company's lease components included in the consolidated balance sheet were as follows: Lease component Classification September 30, 2020 Assets ROU assets - operating lease Other assets $ 84,953 Total ROU assets $ 84,953 Liabilities Current operating lease liability Current liabilities $ 22,356 Long-term operating lease liability Other liabilities 64,436 Total lease liabilities $ 86,792
Lease, Cost [Table Text Block]	Rent expense is recognized on a straight-line basis over the life of the lease. Rent expense consists of the following: Nine months ended September 30, 2020 Operating lease costs $ 18,924 Short term lease cost - Total rent expense $ 18,924
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future minimum lease payments under non-cancellable leases were as follows: September 30, 2020 2020 - remaining three months $ 6,088 2021 24,839 2022 25,585 2023 26,352 2024 8,870 Total future minimum lease payments $ 91,734 Less: Interest (4,942 ) Total operating lease liabilities $ 86,792 Current operating lease liability $ 22,356 Long-term operating lease liability 64,436 Total operating lease liabilities $ 86,792

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Convertible Debt [Table Text Block]	Principal balances of the 2020 Convertible Notes were as follows: September 30, 2020 December 31, 2019 2020 Convertible Notes 3,494,840 - Accrued interest 120,939 - Less beneficial conversion feature discount (934,769 ) - Less options discount (809,649 ) - Less warrants discount (974,669 ) - Less issuance cost (289,171 ) - Total, net of discount $ 607,521 $ -

Notes Payable and Other Relat_2

Notes Payable and Other Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Principal balances of the Related Party loans were as follows: September 30, 2020 December 31, 2019 James Bowdring Family – 2018 Convertible Notes - 45,975 Less discount - (17,151 ) Total, net of discount $ - $ 28,824
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued liabilities balances include accrued directors fees, expenses reports for management and employees for expenses they paid for personally related to travel or normal business expenses. September 30, December 31, 2020 2019 Accounts payable and accrued liabilities $ 5,756 $ 13,018

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	9 Months Ended
	Sep. 30, 2020
Disclosure Text Block Supplement [Abstract]
Schedule of Stock Options Roll Forward [Table Text Block]	The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. The prices represent the closing price of the Company’s Common Stock on the OTCQB Market on the respective dates. Options Outstanding Options Exercisable Number of Shares Price per Share Range Weighted Average Exercise Price Aggregate Intrinsic Value (1) Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value (1) Balance at December 31, 2019 260,018 $ 8.16-9.25 $ 8.41 $ - 11,256 $ 8.16 $ - Forfeited - $ - $ - - - - - Vested - - - - 140,399 6.48 - Exercised - $ - $ - - - - - Granted 328,303 $ 5.76-8.32 $ 6.47 - - - - Balance at September 30, 2020 588,321 $ 5.76-9.25 $ 7.32 $ - 151,655 $ 7.16 $ - (1) The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only.
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Nine Months ended September 30, 2020 2019 Risk-free interest rate range 0.48 to 1.65 % - % Expected life of option-years 5.20 to 5.77 - Expected stock price volatility 110.8 to 128.0 % - % Expected dividend yield - % - % Nine Months ended September 30, 2020 2019 Risk-free interest rate range 0.33% - 0.39 % - % Stock Price $3.00 - $3.95 - % Expected life of warrants and option (years) 5.00 - % Expected stock price volatility 108.2% - 112.5 % - % Expected dividend yield 0 % - %
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of the Company’s common stock over the period commensurate with the expected term of the related instrument. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executives, within the Company. The Company does not currently pay dividends on its common stock nor does it expect to do so in the foreseeable future. Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Life in Years Weighted Average Exercise Price Options Exercisable Weighted Average Exercise Price of Options Exercisable Year ended December 31, 2019 $ 8.16-9.25 260,018 2.6 $ 8.41 11,256 $ 8.16 Nine Months ended September 30, 2020 $ 5.76-9.25 588,321 3.7 $ 7.32 151,655 $ 7.16 Total Intrinsic Value of Options Exercised Total Fair Value of Options Vested Year ended December 21, 2019 - 69,787 Nine months ended September 30, 2020 $ - $ 910,444
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the Company’s aggregate restricted stock awards and restricted stock unit activity during the nine months ended September 30, 2020: Number of Unvested Shares Weighted Average Grant Date Fair Value Aggregate Value of Unvested Shares Balance at December 31, 2019 10,417 $ 9.60 $ 100,000 Granted 56,509 $ 6.98 $ 394,280 Vested (50,871 ) $ 7.63 $ (388,173 ) Forfeitures (- ) $ - $ (- ) Balance at September 30, 2020 16,055 $ 6.61 $ 106,107

Contracts with Customers (Table

Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	For the nine months ended September 30, 2020 and 2019 the source of revenue was derived from: September 30, 2020 September 30, 2019 Domestic Product revenue $ 305,000 $ 615,927 Domestic licensing fee 535,714 535,714 Total revenue $ 840,714 $ 1,151,641

Going Concern (Details)

Going Concern (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ (1,771,827)	$ (1,322,881)	$ (1,444,392)	$ (710,334)	$ (241,552)	$ (458,570)	$ (4,539,100)	$ (1,410,456)
Working Capital (Deficit)	(510,693)						(510,693)		$ 42,330
Stockholders' Equity Attributable to Parent	$ (3,901,944)	$ (3,598,164)	$ (4,435,049)	$ (3,760,606)	$ (3,159,022)	$ (3,102,470)	(3,901,944)	(3,760,606)	$ (3,713,595)	$ (2,724,223)
Net Cash Provided by (Used in) Operating Activities							$ (2,954,823)	$ 2,141,607

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory, Current - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of Inventory, Current [Abstract]
Raw Materials	$ 99,363	$ 44,333
Work in Process	14,823	55,502
Finished Goods	127,298	1,552
Total Inventory	$ 241,484	$ 101,387

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 2,528	$ 2,527	$ 7,583	$ 3,703

Property and Equipment (Detai_2

Property and Equipment (Details) - Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2020
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	6 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years

Property and Equipment (Detai_3

Property and Equipment (Details) - Property, Plant and Equipment - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Accumulated Depreciation	$ (49,730)	$ (42,147)
Total	106,000	93,055
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Property, plant and Equipment, gross	132,513	132,513
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and Equipment, gross	20,528	0
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and Equipment, gross	$ 2,689	$ 2,689

Patents (Details)

Patents (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Patents (Details) [Line Items]
Amortization	$ 452	$ 1,455	$ 1,355	$ 3,423
Trademarks [Member]
Patents (Details) [Line Items]
Finite-Lived Intangible Assets, Period Increase (Decrease)			$ 37,480

Patents (Details) - Schedule of

Patents (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of Finite-Lived Intangible Assets [Abstract]
Total Patents	$ 77,722	$ 77,722
Accumulated Amortization	(71,843)	(70,488)
Patent costs, net	$ 5,879	$ 7,234

Patents (Details) - Schedule _2

Patents (Details) - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Abstract]
2020 – remaining three months	$ 454
2021	1,809
2022	1,809
2023 and thereafter	1,807
Total	$ 5,879	$ 7,234

Patents (Details) - Schedule _3

Patents (Details) - Schedule of Indefinite-Lived Intangible Assets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of Indefinite-Lived Intangible Assets [Abstract]
Total Trademarks	$ 87,347	$ 49,867
Total Trademarks	$ 87,347	$ 49,867

Leases (Details)

Leases (Details)	Sep. 30, 2020
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Term of Contract	5 years
Lessee, Operating Lease, Renewal Term	3 years

Leases (Details) - Lessee, Oper

Leases (Details) - Lessee, Operating Lease, Disclosure - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Assets
ROU assets - operating lease	$ 84,953	$ 101,883
Total ROU assets	84,953
Liabilities
Current operating lease liability	22,356	21,365
Long-term operating lease liability	64,436	$ 81,494
Total lease liabilities	$ 86,792

Leases (Details) - Lease, Cost

Leases (Details) - Lease, Cost	9 Months Ended
	Sep. 30, 2020USD ($)
Lease, Cost [Abstract]
Operating lease costs	$ 18,924
Short term lease cost	0
Total rent expense	$ 18,924

Leases (Details) - Lessee, Op_2

Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Lessee, Operating Lease, Liability, Maturity [Abstract]
2020 - remaining nine months	$ 6,088
2021	24,839
2022	25,585
2023	26,352
2024	8,870
Total future minimum lease payments	91,734
Less: Interest	(4,942)
Total operating lease liabilities	86,792
Current operating lease liability	22,356	$ 21,365
Long-term operating lease liability	$ 64,436	$ 81,494

Notes Payable (Details)

Notes Payable (Details)	Jun. 22, 2020USD ($)	May 31, 2018USD ($)$ / shares	May 31, 2020USD ($)	May 30, 2019USD ($)shares	Apr. 30, 2019USD ($)shares	Feb. 28, 2019USD ($)shares	Aug. 31, 2016USD ($)	Sep. 30, 2020USD ($)$ / shares	Jul. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2018USD ($)shares	Sep. 30, 2020USD ($)$ / shares	Sep. 30, 2019USD ($)shares	Dec. 31, 2019USD ($)
Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount	$ 157,620
Debt Conversion, Original Debt, Amount				$ 25,000	$ 160,000	$ 53,723						$ 0	$ 238,723
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares				3,907	25,000	8,394
Debt Instrument, Convertible, Beneficial Conversion Feature												1,208,163	0
Convertible Notes Payable, Current								$ 0				0
Debt Instrument, Unamortized Discount								$ 0				$ 0		$ 17,151
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares								$ 5.76				$ 5.76
Warrants and Rights Outstanding, Term								5 years	5 years			5 years
Amortization of Debt Discount (Premium)												$ 465,525	297,058
Amortization of Debt Issuance Costs												81,764	$ 0
Converted Account Payable to Promissory Note [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount							$ 131,722
Debt Instrument, Term							3 years
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Interest Payable, Current								$ 0				0
Interest Expense, Debt												489
The 2018 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount		$ 895,000
Debt Instrument, Interest Rate, Stated Percentage		9.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 6.40
Number of Note Holders											3
Debt Conversion, Original Debt, Amount			$ 116,693								$ 200,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares											32,982		37,301
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 895,000
Repayments of Convertible Debt			396,044
The 2018 Convertible Notes [Member] | Principal [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount													$ 235,000
The 2018 Convertible Notes [Member] | Accrued Interest [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount													3,723
The 2018 Convertible Notes [Member] | Principal [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount			125,000
Repayments of Convertible Debt			420,000
The 2018 Convertible Notes [Member] | Accrued Interest [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount			23,318
Repayments of Convertible Debt			94,419
The 2018 Convertible Notes [Member] | Conversion Discount [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount			31,625
Repayments of Convertible Debt			118,375
The 2018 Convertible Notes, Due January 30, 2021 [Member]
Notes Payable (Details) [Line Items]
Convertible Notes Payable		550,000
The 2018 Convertible Notes, Due March 31, 2021 [Member]
Notes Payable (Details) [Line Items]
Convertible Notes Payable		$ 345,000
2020 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount									$ 3,500,000
Debt Instrument, Interest Rate, Stated Percentage									10.00%
Interest Expense, Debt								89,158		$ 0		120,939	0
Convertible Notes Payable								607,521				607,521		0
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares									$ 5.76
Debt Instrument, Convertible, Beneficial Conversion Feature								257,455	$ 1,208,163	0		274,064	0
Debt Conversion, Converted Instrument, Amount			143,640
Debt Issuance Costs, Gross									371,000
Debt Instrument, Unamortized Discount								934,769	$ 1,579,163			934,769		$ 0
Number of Units (in Shares) | shares									303,623
Unit, Exercise Price (in Dollars per share) | $ / shares									$ 8
Unit, Description									each unit consisting of one share of common stock and one warrant to purchase common stock at an exercise price of $9.60 per share
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares									$ 9.60
Proceeds from Issuance of Long-term Debt									$ 3,500,000
Amortization of Debt Discount (Premium)								43,769		0		59,334	0
Amortization of Warrant Discount								52,688		0		$ 71,430	$ 0
Amortization of Debt Issuance Costs								$ 61,187		$ 0
PPP Loan [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Term	18 months
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Debt Instrument, Description	The loan is forgivable up to 100% of the principal balance based upon satisfaction of certain criteria under the Paycheck Protection Program.
Placement Agent Warrants [Member] | 2020 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares									$ 5.76
Class of Warrant or Right, Granted (in Shares) | shares									6,750
Purchase Option Fair Value [Member] | 2020 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Proceeds from Issuance of Long-term Debt									$ 2,200,000
Notes Held by Related Party [Member] | The 2018 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Repayments of Convertible Debt			35,483
Notes Held by Related Party [Member] | The 2018 Convertible Notes [Member] | Principal [Member]
Notes Payable (Details) [Line Items]
Repayments of Convertible Debt			40,000
Notes Held by Related Party [Member] | The 2018 Convertible Notes [Member] | Accrued Interest [Member]
Notes Payable (Details) [Line Items]
Repayments of Convertible Debt			7,355
Notes Held by Related Party [Member] | The 2018 Convertible Notes [Member] | Conversion Discount [Member]
Notes Payable (Details) [Line Items]
Repayments of Convertible Debt			$ 11,872

Notes Payable (Details) - Conve

Notes Payable (Details) - Convertible Debt - 2020 Convertible Notes [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Jul. 31, 2020
Notes Payable (Details) - Convertible Debt [Line Items]
2020 Convertible Notes	$ 3,494,840	$ 0
Accrued interest	120,939	0
Less beneficial conversion feature discount	(934,769)	0	$ (1,579,163)
Less issuance cost	(289,171)	0
Total, net of discount	607,521	0
Equity Option [Member]
Notes Payable (Details) - Convertible Debt [Line Items]
Less options discount	(809,649)	0
Embedded Derivative Financial Instruments [Member]
Notes Payable (Details) - Convertible Debt [Line Items]
Less options discount	$ (974,669)	$ 0

Notes Payable and Other Relat_3

Notes Payable and Other Related Party Transactions (Details) - USD ($)	Aug. 07, 2019	Aug. 31, 2020	May 31, 2020	Mar. 31, 2020	Feb. 29, 2020	Aug. 31, 2019	May 30, 2019	Apr. 30, 2019	Feb. 28, 2019	Jan. 31, 2019	May 31, 2018	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2011	Jun. 30, 2020	Jun. 22, 2020	Nov. 30, 2011	Apr. 30, 2011
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount																				$ 157,620
Debt Conversion, Original Debt, Amount							$ 25,000	$ 160,000	$ 53,723							$ 0	$ 238,723
Interest Expense, Related Party												$ 0	$ 1,271			1,380	4,792
Repayments of Related Party Debt																40,000	97,743
Stock Issued During Period, Shares, Issued for Services (in Shares)		3,750		1,563	1,563	1,562				1,875
Stock Issued During Period, Value, Issued for Services		$ 19,500		$ 11,500	$ 11,500	$ 15,000				$ 26,600
The 2018 Convertible Notes [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount											$ 895,000
Debt Instrument, Interest Rate, Stated Percentage											9.00%
Debt Conversion, Original Debt, Amount			$ 116,693											$ 200,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)											$ 6.40
Immediate Family Member of Management or Principal Owner [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount																						$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%																					10.00%
Debt Conversion, Original Debt, Amount																		$ 25,000
Interest Expense, Related Party													597				1,836
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																			$ 0.2100
Repayments of Related Party Debt	$ 65,197
Immediate Family Member of Management or Principal Owner [Member] | 2011 Notes [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount																					$ 10,000
Debt Instrument, Interest Rate, Stated Percentage																					10.00%
Interest Expense, Related Party													253				749
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																					$ 0.32
Immediate Family Member of Management or Principal Owner [Member] | The 2018 Convertible Notes [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount											$ 40,000
Debt Instrument, Interest Rate, Stated Percentage											9.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)											$ 6.40
Debt Instrument, Increase, Accrued Interest												0	907			1,380	2,692
Immediate Family Member of Management or Principal Owner [Member] | Building [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Operating Leases, Rent Expense																0	1,800
Related Party Transaction, Expenses from Transactions with Related Party												$ 0	$ 2,134			$ 0	$ 8,168
Charles Mulrey and Family [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)											4,687
Sale of Stock, Price Per Share (in Dollars per share)											$ 6.40
Proceeds from Issuance of Common Stock											$ 30,000
One of Directors, Dr. Kevin Doody [Member] | Restricted Stock [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)															93,750,000,000
Stock Issued During Period, Value, Issued for Services															$ 1,530,000

Notes Payable and Other Relat_4

Notes Payable and Other Related Party Transactions (Details) - Schedule of Related Party Transactions - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Related Party Loans	$ 0	$ 28,824
Less discount	0	(17,151)
Immediate Family Member of Management or Principal Owner [Member] | The 2018 Convertible Notes [Member]
Related Party Transaction [Line Items]
Related Party Loans	$ 0	$ 45,975

Notes Payable and Other Relat_5

Notes Payable and Other Related Party Transactions (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable and accrued liabilities	$ 5,756	$ 13,018

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Nov. 05, 2020	Feb. 19, 2020	Aug. 31, 2020	Jun. 30, 2020	May 31, 2020	Mar. 31, 2020	Feb. 29, 2020	Feb. 28, 2020	Jan. 31, 2020	Oct. 31, 2019	Aug. 31, 2019	May 30, 2019	Apr. 30, 2019	Feb. 28, 2019	Jan. 31, 2019	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Oct. 22, 2020	Dec. 31, 2019
Stockholders' Equity (Details) [Line Items]
Stockholders' Equity, Reverse Stock Split	5-for-8	1-for-20
Common Stock, Shares Authorized (in Shares)																200,000,000	200,000,000		125,000,000	200,000,000
Payments of Stock Issuance Costs																$ 106,316	$ 106,316	$ 0
Stock Issued During Period, Shares, Issued for Services (in Shares)			3,750			1,563	1,563				1,562				1,875
Stock Issued During Period, Value, Issued for Services			$ 19,500			$ 11,500	$ 11,500				$ 15,000				$ 26,600
Stockholders' Equity, Other Shares (in Shares)					24
Debt Conversion, Converted Instrument, Shares Issued (in Shares)												3,907	25,000	8,394
Debt Conversion, Original Debt, Amount												$ 25,000	$ 160,000	$ 53,723			$ 0	$ 238,723
2019 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Amortization of ESOP Award										$ 90,000
Stock Issued During Period, Shares, Issued for Services (in Shares)				3,750			1,875
Stock Issued During Period, Value, Issued for Services							$ 15,000
Officer [Member] | 2019 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in Shares)									31,250
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture									$ 221,400
Employee [Member] | 2019 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in Shares)			12,500		3,438			3,125
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture			$ 72,200	$ 22,800	$ 25,930			$ 24,750
Amortization of ESOP Award			$ 12,032		$ 12,804			$ 14,438
Director [Member] | 2019 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in Shares)								3,098
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture								$ 25,000

Stock Options and Warrants (Det

Stock Options and Warrants (Details) - USD ($)	1 Months Ended		3 Months Ended				9 Months Ended		12 Months Ended
	Jan. 31, 2020	Oct. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jul. 31, 2020
Stock Options and Warrants (Details) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term							3 years 255 days		2 years 219 days
Share-based Payment Arrangement, Noncash Expense							$ 852,187	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)							56,509
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in Shares)							50,871
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture			$ 54,703	$ 42,509	$ 303,463
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 5.76				$ 5.76
Warrants and Rights Outstanding, Term			5 years				5 years			5 years
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition			$ 255,797	$ 214,915	$ 381,475
Adjustments to Additional Paid in Capital, Warrant Issued							$ 47,293
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)			6,750				6,750
Convertible Debt [Member]
Stock Options and Warrants (Details) [Line Items]
Number of Units (in Shares)							310,373
Class of Warrant or Right, Granted (in Shares)							310,373
Unit, Exercise Price (in Dollars per share)							$ 8
Unit, Description							one share of common, and a warrant to purchase one share of common stock
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 9.60				$ 9.60
Warrants and Rights Outstanding, Term			5 years				5 years
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition							$ 868,973
Adjustments to Additional Paid in Capital, Warrant Issued							$ 998,818
Minimum [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)							$ 5.76
Maximum [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)							$ 8.32
Restricted Stock [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Payment Arrangement, Noncash Expense			$ 67,202				$ 388,173
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			106,107				$ 106,107
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)							90,412
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in Shares)							50,871
2019 Plan [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)		500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in Shares)	793,093
Share-based Compensation Arrangement by Share-based Payment Award, Description	Plan automatically increases on January 1st of each year, in an amount equal to six percent (6%) of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)							$ 5.44
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term							3 years 255 days
Share-based Payment Arrangement, Noncash Expense			259,547			$ 0	$ 852,187	$ 0
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			$ 2,107,857				$ 2,107,857
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture (in Shares)		12,500
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture		$ 120,000
Amortization of ESOP Award		$ 90,000
2019 Plan [Member] | Minimum [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term		3 years
2019 Plan [Member] | Maximum [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term		10 years

Stock Options and Warrants (D_2

Stock Options and Warrants (Details) - Schedule of Stock Options Roll Forward - USD ($)		9 Months Ended
		Sep. 30, 2020	Dec. 31, 2019
Stock Options and Warrants (Details) - Schedule of Stock Options Roll Forward [Line Items]
Balance, Options Outstanding, Number of Shares (in Shares)		260,018
Balance, Options Outstanding, Weighted Average Exercise Price		$ 7.32	$ 8.41
Balance, Options Outstanding, Aggregate Intrinsic Value (in Shares)		151,655	11,256
Balance, Options Exercisable, Number of Shares		$ 7.16	$ 8.16
Balance, Options Exercisable, Weighted Average Exercise Price (in Dollars)	[1]
(in Dollars)	[1]
Vested (in Shares)		140,399
Vested, Options Exercisable, Number of Shares		$ 6.48
Granted, Options Outstanding (in Shares)		328,303
Granted, Options Outstanding		$ 6.47
Balance, Options Outstanding, Number of Shares (in Shares)		588,321
Minimum [Member]
Stock Options and Warrants (Details) - Schedule of Stock Options Roll Forward [Line Items]
Balance, Options Outstanding, Price per Share Range		$ 8.16
Granted, Options Outstanding		5.76
Balance, Options Outstanding, Price per Share Range		5.76
Maximum [Member]
Stock Options and Warrants (Details) - Schedule of Stock Options Roll Forward [Line Items]
Balance, Options Outstanding, Price per Share Range		9.25
Granted, Options Outstanding		8.32
Balance, Options Outstanding, Price per Share Range		$ 9.25
[1]	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only.

Stock Options and Warrants (D_3

Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement, Option [Member]
Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range		0.00%
Expected life		0 years
Expected stock price volatility		0.00%
Expected dividend yield	0.00%	0.00%
Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range	0.48%
Expected life	5 years 73 days
Expected stock price volatility	110.80%
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range	1.65%
Expected life	5 years 281 days
Expected stock price volatility	128.00%
Option and Warrants Issued with Convertible Debt [Member]
Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Expected life	5 years
Expected dividend yield	0.00%
Option and Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range	0.33%
Stock Price (in Dollars per share)	$ 3
Expected stock price volatility	108.20%
Option and Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range	0.39%
Stock Price (in Dollars per share)	$ 3.95
Expected stock price volatility	112.50%

Stock Options and Warrants (D_4

Stock Options and Warrants (Details) - Share-based Payment Arrangement, Option, Exercise Price Range - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Balance, Options Outstanding, Number of Shares (in Shares)	588,321	260,018	260,018
Weighted Average Remaining Life in Years	3 years 255 days	2 years 219 days
Weighted Average Exercise Price	$ 7.32	$ 8.41
Options Exercisable (in Shares)	151,655	11,256
Weighted Average Exercise Price of Options Exercisable	$ 7.16	$ 8.16
Total Intrinsic Value of Options Exercised (in Dollars)	$ 0	$ 0
Total Fair Value of Options Vested (in Dollars)	$ 910,444	$ 69,787
Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices	$ 5.76	$ 8.16	$ 8.16
Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices	$ 9.25	$ 9.25	$ 9.25

Stock Options and Warrants (D_5

Stock Options and Warrants (Details) - Nonvested Restricted Stock Shares Activity - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Nonvested Restricted Stock Shares Activity [Abstract]
Balance, Number of Unvested Shares	16,055	10,417
Balance, Weighted Average Grant Date Fair Value	$ 6.61	$ 9.60
Balance, Aggregate Value of Unvested Shares	$ 106,107	$ 100,000
Granted, Number of Unvested Shares	56,509
Granted, Weighted Average Grant Date Fair Value	$ 6.98
Granted, Aggregate Value of Unvested Shares	$ 394,280
Vested, Number of Unvested Shares	(50,871)
Vested, Weighted Average Grant Date Fair Value	$ 7.63
Vested, Aggregate Value of Unvested Shares	$ (388,173)
Forfeitures, Number of Unvested Shares	0
Forfeitures, Weighted Average Grant Date Fair Value	$ 0
Forfeitures, Aggregate Value of Unvested Shares	$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 0	$ 30,509	$ 0	$ 30,509
Effective Income Tax Rate Reconciliation, Percent			0.00%	0.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jan. 17, 2020	Oct. 10, 2019	Aug. 07, 2019	Jan. 17, 2017	Jan. 15, 2017	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Apr. 30, 2011
Commitments and Contingencies (Details) [Line Items]
Repayments of Related Party Debt						$ 40,000	$ 97,743
Salary and Wage, Officer, Excluding Cost of Good and Service Sold		$ 260,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price						$ 6.47
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures						328,303
Immediate Family Member of Management or Principal Owner [Member]
Commitments and Contingencies (Details) [Line Items]
Repayments of Related Party Debt			$ 65,197
Debt Instrument, Term			30 days
Debt Instrument, Interest Rate, Stated Percentage			10.00%						10.00%
Debt Instrument, Convertible, Terms of Conversion Feature			Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $0.96 and $0.32, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.2100)
Debt Instrument, Convertible, Conversion Price								$ 0.2100
Deferred Compensation Arrangement with Individual, Description		Mr. Shum is eligible to earn bonus compensation of up to $75,000 bonus upon a successful up-listing to the NASDAQ exchange. All other bonus amounts will be determined by the Board of Directors, in their sole discretion.
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited		12,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		202,599
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 8.16
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Chief Operating Officer [Member]
Commitments and Contingencies (Details) [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 6.84
Employment Agreement, Annual Base Salary					$ 220,000
Employment Agreement, Bonus Decription					target annual incentive bonus of up to 50% of his base salary if the Company achieves goals and objectives determined by the board of directors
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture				31,250
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures				125,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	One quarter of the Option vested upon grant, and the remainder vests in monthly increments over a period of two years from the date of grant.

Contracts with Customers (Detai

Contracts with Customers (Details) - USD ($)	Jan. 16, 2020	Sep. 20, 2019	Sep. 19, 2019	Sep. 11, 2019	Jan. 14, 2019	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Contracts with Customers (Details) [Line Items]
Proceeds from License Fees Received					$ 5,000,000			$ 5,000,000
Potential Licensing Fee					$ 3,000,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period					7 years
Deferred Revenue, Revenue Recognized						$ 178,572	$ 357,143
Deferred Revenue						$ 3,750,000	$ 3,750,000	$ 4,285,715
Joint Venture, Ownership Percentage	50.00%
Sudan, Uganda, and Ethiopia [Member]
Contracts with Customers (Details) [Line Items]
Distribution Agreement, Term		1 year
NIGERIA
Contracts with Customers (Details) [Line Items]
Distribution Agreement, Term				1 year
JORDAN
Contracts with Customers (Details) [Line Items]
Distribution Agreement, Term			1 year

Contracts with Customers (Det_2

Contracts with Customers (Details) - Disaggregation of Revenue - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 336,071	$ 303,571	$ 840,714	$ 1,151,641
Domestic Physicians [Member]
Disaggregation of Revenue [Line Items]
Revenue			305,000	615,927
Domestic Licensing & Distribution Fee [Member]
Disaggregation of Revenue [Line Items]
Revenue			$ 535,714	$ 535,714

Investment in Joint Ventures (D

Investment in Joint Ventures (Details)	9 Months Ended
	Sep. 30, 2020USD ($)
INVO Centers, Arrendondo and Ramirez [Member]
Investment in Joint Ventures (Details) [Line Items]
Payments to Acquire Interest in Joint Venture	$ 23,517
Other Investments [Member]
Investment in Joint Ventures (Details) [Line Items]
Payments to Acquire Interest in Joint Venture	$ 9,157

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions	Nov. 12, 2020	Nov. 16, 2020
Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		109
Common Stock, Capital Shares Reserved for Future Issuance	3,625,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.0001
Sale of Stock, Price Per Share (in Dollars per share)	$ 3.20
Proceeds from Issuance or Sale of Equity (in Dollars)	$ 10.1
Offering, Option to Underwriters [Member]
Subsequent Events (Details) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	543,750